← Back to Search

Cardiac Myosin Inhibitor

Mavacamten- Dose A for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 1 month
Awards & highlights

Study Summary

The purpose of this study is to evaluate the effects on the single-dose drug levels of mavacamten in healthy participants.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))
Maximum observed plasma concentration (Cmax)
Secondary outcome measures
Number of participants with adverse events (AEs)
Number of participants with clinical laboratory evaluation abnormalities
Number of participants with electrocardiogram (ECG) abnormalities
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Mavacamten- Dose BExperimental Treatment1 Intervention
Group II: Mavacamten- Dose AExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mavacamten
2022
Completed Phase 1
~340

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,645 Previous Clinical Trials
4,130,841 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
2022. "A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05362045.
~54 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top